Gaithersburg, MD, United States of America

Brandon Higgs

USPTO Granted Patents = 11 (Patent Applications = 12)

EPO Patents = 3 (Patent Applications = 12)

Average Co-Inventor Count = 8.1

ph-index = 4

Forward Citations = 64(Granted Patents)

Company Filing History:

Ocimum Biosolutions, Inc.

where one patent can have more than one assignee

Years Active: 2008-2023

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11827706 - Anti-B7-H1 antibodies for treating tumors (2023-11-28),

2. 11220541 - CCL20 as a predictor of clinical response to IL23-antagonists (2022-01-11),

3. 11016099 - Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers (2021-05-25),

4. 10829557 - Anti-B7-H1 antibodies for treating tumors (2020-11-10),

5. 10336823 - Anti-B7-H1 antibodies for treating tumors (2019-07-02),

6. 9493570 - Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies (2016-11-15),

7. 7590493 - Methods for determining hepatotoxins (2009-09-15),

8. 7469185 - Primary rat hepatocyte toxicity modeling (2008-12-23),

9. 7447594 - Molecular cardiotoxicology modeling (2008-11-04),

10. 7426441 - Methods for determining renal toxins (2008-09-16),

11. 7415358 - Molecular toxicology modeling (2008-08-19),

Title: The Innovative Contributions of Brandon Higgs

Introduction

Brandon Higgs is a notable inventor based in Gaithersburg, MD (US), recognized for his significant contributions to the field of biotechnology. With a total of 11 patents to his name, he has made strides in developing innovative treatments for various medical conditions. His work primarily focuses on cancer therapies and biomarkers for disease prediction.

Latest Patents

Among his latest patents, one of the most impactful is the development of Anti-B7-H1 antibodies for treating tumors. This invention provides methods for treating B7-H1-expressing tumors by administering an effective amount of MEDI4736 or an antigen-binding fragment thereof. Another significant patent involves CCL20 as a predictor of clinical response to IL23-antagonists. This invention relates to using the Chemokine (C-C motif) ligand 20 (CCL20) as a biomarker to identify patients suffering from IL23-mediated diseases, such as Crohn's disease, who may respond to anti-IL23 treatment.

Career Highlights

Brandon has worked with prominent companies in the biotechnology sector, including MedImmune Limited and Ocimum Biosolutions, Inc. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects that have advanced medical science.

Collaborations

Throughout his career, Brandon has collaborated with esteemed colleagues, including Donna Mendrick and Mark Porter. These partnerships have fostered an environment of innovation and have contributed to the success of his projects.

Conclusion

Brandon Higgs exemplifies the spirit of innovation in the biotechnology field through his patents and collaborations. His work continues to influence the development of effective treatments for complex medical conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

12 patents pending:

Please report any incorrect information to support@idiyas.com

3 patents (EPO):

Please report any incorrect information to support@idiyas.com

12 patents pending (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.